Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Forecasted to Post FY2020 Earnings of ($8.32) Per Share


Share on StockTwits

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at William Blair reduced their FY2020 earnings per share estimates for Sarepta Therapeutics in a report issued on Tuesday, January 12th. William Blair analyst T. Lugo now forecasts that the biotechnology company will earn ($8.32) per share for the year, down from their prior estimate of ($8.21). William Blair also issued estimates for Sarepta Therapeutics’ Q4 2020 earnings at ($2.03) EPS, Q1 2021 earnings at ($2.13) EPS, Q2 2021 earnings at ($1.91) EPS, Q3 2021 earnings at ($1.88) EPS, Q4 2021 earnings at ($2.07) EPS and FY2021 earnings at ($7.99) EPS.

A number of other brokerages have also recently commented on SRPT. Royal Bank of Canada reduced their target price on shares of Sarepta Therapeutics from $200.00 to $143.00 and set an “outperform” rating for the company in a research report on Friday, January 8th. UBS Group cut shares of Sarepta Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday. Smith Barney Citigroup cut shares of Sarepta Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday. JPMorgan Chase & Co. cut shares of Sarepta Therapeutics from an “overweight” rating to an “underweight” rating and set a $96.00 price objective for the company. in a research report on Friday, January 8th. Finally, BidaskClub cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 6th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and sixteen have assigned a buy rating to the stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $160.38.

Shares of NASDAQ SRPT opened at $87.22 on Thursday. The firm has a 50-day simple moving average of $153.98 and a 200-day simple moving average of $148.77. The stock has a market capitalization of $6.88 billion, a price-to-earnings ratio of -12.42 and a beta of 1.82. The company has a quick ratio of 6.42, a current ratio of 6.93 and a debt-to-equity ratio of 0.67. Sarepta Therapeutics has a 52 week low of $78.06 and a 52 week high of $181.83.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($2.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.89) by ($0.61). The company had revenue of $143.92 million for the quarter, compared to analysts’ expectations of $133.69 million. Sarepta Therapeutics had a negative net margin of 117.80% and a negative return on equity of 53.02%. The business’s revenue for the quarter was up 45.3% on a year-over-year basis. During the same period in the previous year, the business earned ($1.14) earnings per share.

A number of institutional investors have recently modified their holdings of the stock. CIBC Asset Management Inc lifted its stake in Sarepta Therapeutics by 2.5% in the third quarter. CIBC Asset Management Inc now owns 2,796 shares of the biotechnology company’s stock worth $393,000 after acquiring an additional 69 shares during the last quarter. US Bancorp DE raised its holdings in Sarepta Therapeutics by 4.3% during the third quarter. US Bancorp DE now owns 2,439 shares of the biotechnology company’s stock worth $343,000 after purchasing an additional 100 shares in the last quarter. Spearhead Capital Advisors LLC raised its holdings in Sarepta Therapeutics by 6.4% during the third quarter. Spearhead Capital Advisors LLC now owns 1,871 shares of the biotechnology company’s stock worth $263,000 after purchasing an additional 113 shares in the last quarter. OneAscent Financial Services LLC raised its holdings in Sarepta Therapeutics by 4.1% during the fourth quarter. OneAscent Financial Services LLC now owns 3,379 shares of the biotechnology company’s stock worth $576,000 after purchasing an additional 133 shares in the last quarter. Finally, Pathstone Family Office LLC raised its holdings in Sarepta Therapeutics by 270.9% during the third quarter. Pathstone Family Office LLC now owns 204 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 149 shares in the last quarter. Institutional investors own 92.70% of the company’s stock.

In other news, insider Joseph Bratica sold 1,115 shares of the firm’s stock in a transaction that occurred on Friday, December 11th. The shares were sold at an average price of $165.00, for a total value of $183,975.00. Following the completion of the transaction, the insider now owns 9,255 shares of the company’s stock, valued at $1,527,075. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 5.90% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

Recommended Story: When is a capital gain realized?

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.